Mitchell Fane was named assistant professor in the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center.
Jeffrey M. Farma was appointed chair of surgery at Fox Chase Cancer Center.
Mitchell Fane named assistant professor at Fox Chase
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Fox Chase Cancer Center received a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg. This gift is the culmination of many years of support, bringing Greenberg’s total giving to nearly $20 million for pancreatic cancer research at Fox Chase.
Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy.
Daniel M. Geynisman was named the editor-in-chief of JNCCN—Journal of the National Comprehensive Cancer Network.
ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.
When cancer breaches the brain, it can be difficult for treatment to follow.
